Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06605417
Recruiting Observational

Understanding the Transition from Normal Melanocytes to Nevus to Melanoma

NCT06605417 · tracked via the Priya Life Science France tracker
Sponsor
Fundacion Clinic per a la Recerca Biomédica
Phase
Observational
Started
2024-01-01
Last updated
2025-02-27

Condition(s) studied

Congenital Melanocytic NeviMelanoma, SkinNevi and Melanomas

Investigational drug(s) / intervention(s)

MethylomicsRNA sequencingSpatial transcriptomicsLiquid biopsy

Methylomics: Methylomics analysis of FFPE blocks and frozen tissues

RNA sequencing: RNA sequencing of FFPE blocks and frozen tissues

Spatial transcriptomics: Spatial transcriptomics of FFPE blocks and frozen tissues

Liquid biopsy: cfDNA characterization extracted from blood/saliva

Study summary

The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are:

* To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients.
* To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources.
* To test pre-clinical strategies to best model and improve patient response.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion criteria: * Congenital nevus with estimated size of 20 cm * Be over 18 years of age Exclusion criteria: * No available biological material * Not having signed the informed consent

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
French National Institute of Health and Medical Research Marseille France Recruiting
Hospital Clínic de Barcelona (Dermatology service) Barcelona Spain Recruiting

Other trials for the same condition

One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy Active, not recruiting
Impact and Lived Experience of Parents of a Child With a Large or Giant Congenital Melanocytic Nevus Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06605417 on ClinicalTrials.gov ↗ ← All trials in France